An interventional study of Text Message Reminders and Sun Protection Education Modules in Skin Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by University of Utah · Not applicable, Interventional, and Prevention
Among 379 studies in Skin Neoplasms with a site in United States — 62 open to participants now, 96 under way, 7 of them phase 3. Skin Neoplasms · United States.
Among the 379 studies in Skin Neoplasms with a site in United States, this one is the 208th largest by planned enrollment of the 288 interventional ones that give a count, is one of 16 that started in 2026, is one of 96 with no phase, reaches primary completion later than 48 of the 94 other live ones, and was the 372nd registered.
604 studies on the registry are indexed under Skin Neoplasms; 126 are open to participants now.
Browse Skin Neoplasms studies →62 of the 379 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 13+ · Healthy volunteers
Marissa Lobl · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Karam Khaddour, MD, MS · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Skin Neoplasms studies recruiting now, 84 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 29 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 114 · Phase 3 26 · Phase 4 11
First in 1977; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 55 across 408 interventional studies indexed under Skin Neoplasms.
Median enrollment 44 across the 288 interventional studies, 149 across the 80 observational. Of the 258 that completed or were terminated, 92 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 379 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 8 studies filed under Skin Neoplasms — fewer than ten, so there is no comparison to draw.
33 of the studies in Skin Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT05634252Phase 3University of UtahUndergraduate Skin Cancer Prevention Trial | 2027-09-04 |
| NCT07201376Dartmouth-Hitchcock Medical CenterAssessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically | 2026-11 |
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
Among the 379 studies in Skin Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of this proposal is to refine a mobile-health (mHealth) system to reduce excessive unprotected sun exposure among young adults.
Participants will complete a 4-week intervention with all intervention components delivered through the mHealth application. Intervention components include Text Message Reminders, Sun Protection Education Modules, Action Planning Module, and UV Radiation (UVR) Weather Information.
mHealth tools provide an ideal opportunity for reducing young adults' UVR exposure. mSHIELD intervention components were selected to target key constructs (e.g., self-efficacy, barrier reduction) within Social Cognitive Theory (SCT) which are associated with sun protection behaviors. The initial concept for the mSHIELD intervention includes the following four components: real-time UVR alerts and feedback; UVR weather forecasts; text messages; and action planning. Although these components provide a good fit with SCT constructs and utilize evidence-based behavior change strategies, they have rarely been used in the context of mHealth for sun protection, and this will be the first mHealth intervention for sun protection to apply all four of these components simultaneously. Therefore, prior to testing mSHIELD in a large study, it will be important to refine components based on user preferences and pilot tests.
To test the pilot intervention, participants will complete a 4-week intervention with all intervention components delivered through the study application. Intervention components will include: text messages, sun protection education modules, an action planning module, and UVR/weather information. The modules/components are used for the entire 4-week intervention period. Immediately following the 4-week intervention, participants will be asked to complete a post-intervention survey and study interview. Participants will also be asked to complete a survey one month post-intervention. Participants will receive up to 5 reminders to complete each study activity through each of their approved communication methods (e.g., email).
Data collected at the one-month post-intervention surveys will be analyzed and compared to baseline values. For this study, the criteria for a clinically significant impact will be that a participant reports no sunburns and now frequently uses sunscreen and at least one other sun protection method during outdoor time; a priori, a benchmark of at least 50% of participants reaching this criteria is set to indicate whether the intervention can proceed to larger-scale testing or if further refinements are needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will complete a 4-week intervention with all intervention components delivered through the study application. Intervention components will include: text messages, sun protection education modules, an action planning module, and ultraviolet radiation (UVR)/weather information. The modules/components are used for the entire 4-week intervention period.
Behavioral: Text Message Reminders · Behavioral: Sun Protection Education Modules · Behavioral: Action Planning Module · Behavioral: UV Radiation (UVR) Weather Information
Participants will receive text message reminders twice a week. These messages will remind participants to use sunscreen or other forms of sun protection and will include brief facts about sun safety and environmental risks.
The education section consists of 5 modules on sun protection basics, ultraviolet (UV) exposure, skin health, sunscreen use, and tanning. Each module takes about 5 to 10 minutes to read.
The app will guide participants through creating a specific plan for using sun protection during a routine outdoor activity. Completing an action plan takes about 5 minutes. Participants will be asked to complete two action plans during the study and prompted to review these plans weekly.
The UVR Weather feature displays information similar to what is available in many weather apps, with a focus on the sunburn risk hours. The display also shows different levels of UV risk throughout the day and indicates the current UV risk based on real-time UV Index. Participants will receive a daily notification summarizing the UV information for that day.
Proportion of Participants with a Clinically Significant Impact
To determine whether a prototype mHealth system improves use of sun protection strategies among young adults. Data at the one-month post-intervention surveys will be analyzed and compared to baseline values. For this study, the criteria for a clinically significant impact will be that a participant reports no sunburns and now frequently uses sunscreen and at least one other sun protection method during outdoor time. This outcome measure will report the proportion of participants with a clinically significant impact.
Time frame: up to 2 months from baseline
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.
Of 94 non-industry interventional studies with no phase under Skin Neoplasms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 13 months is below that.
Counting every sponsor, half of 116 studies reached it within 27 months; a quarter within 10 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.